Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats

被引:43
|
作者
Anderes, KL [1 ]
Luthin, DR [1 ]
Castillo, R [1 ]
Kraynov, EA [1 ]
Castro, M [1 ]
Hood, KN [1 ]
Gregory, ML [1 ]
Pathak, VP [1 ]
Christie, LC [1 ]
Paderes, G [1 ]
Vazir, H [1 ]
Ye, Q [1 ]
Anderson, MB [1 ]
May, JM [1 ]
机构
[1] La Jolla Agouron Pharmaceut Inc, Pfizer Global Res & Dev, Res Pharmacol, San Diego, CA 92121 USA
关键词
D O I
10.1124/jpet.102.046656
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Gonadotropin-releasing hormone ( GnRH) receptor antagonists have potential in treating numerous hormone-dependent pathologies including cancers of the prostate, breast, and ovary, endometriosis, and fertility disorders. An unmet clinical need exists for an orally available GnRH receptor antagonist. Guided by structure-activity relationships, ligand-based targeted library designs, and biomarker measurements, our discovery efforts have yielded a novel, small molecule GnRH receptor antagonist, 5-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthalenyl) methyl]-N-(2,4,6-trimethoxyphenyl)-2-furamide (CMPD1). CMPD1 bound with low nanomolar affinities to human, rat, and mouse GnRH receptors (6.0, 3.8, and 2.2 nM, respectively). CMPD1 was more than 100-fold selective for GnRH receptors versus various G-protein-coupled receptors and other enzymes and ion channels. In cells expressing recombinant rat GnRH receptors, CMPD1 was a competitive antagonist of GnRH-stimulated increases in extracellular acidification rates in Cytosensor microphysiometer assays. In cells expressing recombinant human GnRH receptors, CMPD1 was a potent inhibitor of GnRH-stimulated total inositol phosphate accumulation. The effects of CMPD1 on circulating levels of luteinizing hormone (LH) and testosterone were studied in castrated and intact male rats, respectively. Intravenous and oral administration of CMPD1 dose dependently suppressed GnRH-mediated elevations of LH in castrated male rats and testosterone in gonadintact male rats. Moreover, CMPD1, when given at 20 mg/kg i.v. to intact male rats, inhibited the elevations of LH and testosterone stimulated by the superagonist of GnRH, [D-Ala(6), desGly(10)] GnRH ( GnRH-A). These data suggest that CMPD1 is a potent, selective, orally active GnRH receptor antagonist that may have potential application as a therapeutic agent for treating hormone-dependent cancers and diseases.
引用
收藏
页码:688 / 695
页数:8
相关论文
共 50 条
  • [21] INTRACELLULAR GONADOTROPIN-RELEASING-HORMONE IMMUNOREACTIVITY IN GONADOTROPHS OF INTACT OR CASTRATED MALE-RATS - SEMIQUANTITATIVE ESTIMATION OF TESTOSTERONE AND GNRH ANTAGONIST TREATMENT
    MOREL, G
    AUBERT, ML
    DUBOIS, PM
    ACTA ANATOMICA, 1994, 149 (01): : 46 - 54
  • [22] ULTRASTRUCTURAL CHARACTERIZATION OF GONADOTROPIN-RELEASING HORMONE (GNRH)-PRODUCING NEURONS
    JENNES, L
    STUMPF, WE
    SHEEDY, ME
    JOURNAL OF COMPARATIVE NEUROLOGY, 1985, 232 (04) : 534 - 547
  • [23] Discovery of Small Molecule Agonist of Gonadotropin-Releasing Hormone Receptor (GnRH1R)
    Yang, Xin
    Lin, Guifeng
    Xia, Anjie
    Liu, Jingming
    Zhang, Shiyu
    Zhou, Pei
    Wang, Yiwei
    Zhang, Jiahao
    Zhou, Yangli
    Chen, Pei
    Wang, Yifei
    Zheng, Tao
    Li, Linli
    Yang, Shengyong
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2022, 62 (20) : 5009 - 5022
  • [24] OVARIAN GONADOTROPIN-RELEASING HORMONE (GNRH) RECEPTORS - CHARACTERIZATION, DISTRIBUTION, AND INDUCTION BY GNRH
    PIEPER, DR
    RICHARDS, JS
    MARSHALL, JC
    ENDOCRINOLOGY, 1981, 108 (04) : 1148 - 1155
  • [25] INVITRO PITUITARY RESPONSIVENESS TO GONADOTROPIN-RELEASING HORMONE (LH-RH) IN INTACT AND CASTRATED MALE AND FEMALE RATS
    SANDERS, FJ
    MAY, PB
    DONABEDIAN, RK
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1975, 3 (01) : 71 - 80
  • [26] EFFECT OF PASSIVE-IMMUNIZATION TO GONADOTROPIN-RELEASING HORMONE (GNRH) USING GNRH ANTISERUM ON THE MITOTIC-ACTIVITY OF GONADOTROPHS IN CASTRATED MALE-RATS
    SAKAI, T
    INOUE, K
    HASEGAWA, Y
    KUROSUMI, K
    ENDOCRINOLOGY, 1988, 122 (06) : 2803 - 2808
  • [27] Progress towards the development of nonpeptide orally-active gonadotropin-releasing hormone (GnRH) antagonists: therapeutic implications
    Millar, RP
    Zhu, YF
    Chen, C
    Struthers, RS
    BRITISH MEDICAL BULLETIN, 2000, 56 (03) : 761 - 772
  • [28] Relugolix: A Novel Gonadotropin-Releasing Hormone Antagonist for Prostate Cancer
    Babu, Merin
    Pavithran, Keechilat
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2021, 12 (01) : 26 - 28
  • [29] SUPPRESSION AND RECOVERY OF PITUITARY GONADOTROPIN-SECRETION IN INTACT AND ORCHIDECTOMIZED RATS TREATED NEONATALLY WITH A GONADOTROPIN-RELEASING HORMONE ANTAGONIST
    KOLHO, KL
    HUHTANIEMI, I
    JOURNAL OF ENDOCRINOLOGY, 1989, 122 (02) : 519 - 526
  • [30] Characterization of gonadotropin-releasing hormone (GnRH) in the Atlantic hagfish Myxine glutinosa
    Kavanaugh, SI
    Nozaki, M
    Sower, SA
    JOURNAL OF EXPERIMENTAL ZOOLOGY PART A-ECOLOGICAL GENETICS AND PHYSIOLOGY, 2006, 305A (02): : 139 - 139